Significantly, recent data from Pliant Therapeutics, which developed bexotegrast, showed that this drug targets a subgroup of CTHRC1-positive myofibroblasts responsible for excessive collagen production in pulmonary fibrosis [124]. This evidence concerns the gene CTHRC1 and pulmonary fibrosis.